Placeholder Abstract Submission Guidelines for Clinical Trials

All clinical trials abstracts must be submitted by January 12, 2023. A placeholder for a clinical trials abstract may be submitted to one of the Clinical Trials Placeholder categories (PL) only if the trial is ongoing, and final data are not available by the January 12 submission deadline but are expected to be collected between January 12 and February 7.

The placeholder abstract must be submitted by January 12; a request will be sent to the submitting author to submit the updated final abstract by February 7.

- Placeholder abstracts may be submitted for any phase trial (placeholder abstracts are not permitted for Trials in Progress.)
- A placeholder abstract should only be submitted if final data from an ongoing trial are not available by the January 12 deadline.
- Placeholder abstracts must be submitted to the appropriate category by January 12 and should include a tentative title, the full author list and disclosures, background information, and materials and methods. A description of any data that will be submitted with the final abstract should be added, including primary clinical endpoints, and dates and plans for the data analysis.
- A request will be sent to the submitting author to submit the updated final abstract by February 7.
- The Clinical Trials Committee will assess the placeholder abstract submission and then conduct a rapid review of the final abstract.

Placeholder Abstract Categories:
- PL01 Clinical Trials for COVID-19
  - Phase I Clinical Trials
  - Phase II Clinical Trials
  - Phase III Clinical Trials
  - Phase IV, Observational, and Expanded Access Clinical Trials
- PL02 First-in-Human Phase I Clinical Trials
- PL03 Phase I Adult Clinical Trials
- PL04 Phase II Adult Clinical Trials
- PL05 Phase III Adult Clinical Trials

For additional information on clinical trial abstract submissions, view the Spotlight on Clinical Trials page: https://www.aacr.org/meeting/aacr-annual-meeting-2023/spotlight-on-clinical-trials/